Show simple item record

dc.contributor.authorIwamoto, M
dc.contributor.authorCalzia, A
dc.contributor.authorDublineau, A
dc.contributor.authorRouet, F
dc.contributor.authorNouhin, J
dc.contributor.authorYann, S
dc.contributor.authorPin, S
dc.contributor.authorSun, C
dc.contributor.authorSann, K
dc.contributor.authorDimanche, C
dc.contributor.authorLastrucci, C
dc.contributor.authorCoulborn, R
dc.contributor.authorMaman, D
dc.contributor.authorDousset, JP
dc.contributor.authorLoarec, A
dc.date.accessioned2019-02-26T17:24:05Z
dc.date.available2019-02-26T17:24:05Z
dc.date.issued2018-12-03
dc.date.submitted2019-02-15
dc.identifier.citationField evaluation of GeneXpert® (Cepheid) HCV performance for RNA quantification in a genotype 1 and 6 predominant patient population in Cambodia. 2019, 26 (1):38-47 J. Viral Hepat.en
dc.identifier.issn1365-2893
dc.identifier.pmid30199587
dc.identifier.doi10.1111/jvh.13002
dc.identifier.urihttp://hdl.handle.net/10144/619344
dc.description.abstractGeneXpert® (Cepheid) is the only WHO prequalified platform for hepatitis C virus (HCV) nucleic acid amplification testing that is suitable for point-of-care use in resource-limited contexts. However, its application is constrained by the lack of evidence on genotype 6 (GT6) HCV. We evaluated its field performance among a patient population in Cambodia predominantly infected with GT6. Between August and September 2017, we tested plasma samples obtained from consenting patients at Médecins Sans Frontières' HCV clinic at Preah Kossamak Hospital for HCV viral load (VL) using GeneXpert® and compared its results to those obtained using COBAS® AmpliPrep/Cobas® TaqMan® HCV Quantitative Test, v2.0 (Roche) at the Institut Pasteur du Cambodge. Among 769 patients, 77% of the seropositive patients (n = 454/590) had detectable and quantifiable VL using Roche and 43% (n = 195/454) were GT6. The sensitivity and specificity of GeneXpert® against Roche were 100% (95% CI 99.2, 100.0) and 98.5% (95% CI 94.8, 99.8). The mean VL difference was -0.01 (95% CI -0.05, 0.02) log10  IU/mL for 454 samples quantifiable on Roche and -0.07 (95% CI -0.12, -0.02) log10  IU/mL for GT6 (n = 195). The limit of agreement (LOA) was -0.76 to 0.73 log10  IU/mL for all GTs and -0.76 to 0.62 log10 IU/mL for GT6. Twenty-nine GeneXpert® results were outside the LOA. Frequency of error and the median turnaround time (TAT) for GeneXpert® were 1% and 0 days (4 days using Roche). We demonstrated that the GeneXpert® HCV assay has good sensitivity, specificity, quantitative agreement, and TAT in a real-world, resource-limited clinical setting among GT6 HCV patients.en
dc.language.isoenen
dc.publisherWiley-Blackwellen
dc.rightsArchived with thanks to Journal of Viral Hepatitisen
dc.titleField evaluation of GeneXpert® (Cepheid) HCV performance for RNA quantification in a genotype 1 and 6 predominant patient population in Cambodia.en
dc.identifier.journalJournal of Viral Hepatitisen
refterms.dateFOA2019-02-26T17:24:06Z


Files in this item

Thumbnail
Name:
Iwamoto et al - 2018 - Field ...
Size:
758.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record